Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronald Preblick

Showing results (11-20 of 33) with videos related to

Pageof 4
Sort By:
Journal of Comparative Effectiveness Research|June 30, 2023
Clinical and economic outcomes associated with use of anti-arrhythmic drugs versus ablation in atrial fibrillationJennifer Ken-Opurum, Sesha Ss Srinivas, Seojin Park, et al.
BMC Family Practice|November 8, 2008
Improved persistence and adherence to diuretic fixed-dose combination therapy compared to diuretic monotherapyBimal V Patel, Rosemay A Remigio-Baker, Patrick Thiebaud, et al.
Journal of Health Economics and Outcomes Research|May 1, 2025
Healthcare Resource Utilization and Costs Related to Falls and Fractures Among People With Type 2 Diabetes Receiving Basal Insulin: The FRAGILE StudyGuillermo E Umpierrez, Elizabeth K Pogge, Xuan Li, et al.
Journal of Medical Economics|November 2, 2023
The economic value of insulin glargine 300 U/mL (Gla-300) in people ≥18 years of age with type 2 diabetes mellitus: a value-based economic model from a U.S. payer perspectiveEkaterina Ponomareva, Luke Schmerold, Srinivas Sss, et al.
Transplantation and Cellular Therapy|May 11, 2026
Impact of Chronic GVHD on Patient and Caregiver Experiences in the United States: A Retrospective Social Media AnalysisShernan Holtan, Meredith Cowden, Claudine Derrien-Connors, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|January 24, 2026
Economic Benefits of T-cell-depleting Induction in Deceased Donor Kidney Transplant RecipientsDavid Axelrod, Krista L Lentine, Huiling Xiao, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|September 6, 2007
Effects of initial antihypertensive drug class on patient persistence and compliance in a usual-care setting in the United StatesBimal V Patel, Rosemay A Remigio-Baker, Devi Mehta, et al.
Pharmacoeconomics - Open|January 31, 2020
Burden of Cardiovascular Disease in Adult Patients with Type 1 Diabetes in the USSteve Edelman, Fang Liz Zhou, Ronald Preblick, et al.
Clinical Diabetes : a Publication of the American Diabetes Association|July 17, 2023
Real-World Persistence, Adherence, Hypoglycemia, and Health Care Resource Utilization in People With Type 2 Diabetes Who Continued With the Second-Generation Basal Insulin Analog Insulin Glargine 300 Units/mL or Switched to a First-Generation Basal Insulin (Insulin Glargine 100 Units/mL or Detemir 100)Steven Edelman, Jennifer Goldman, Daniel C Malone, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|September 16, 2020
Patient and caregiver preferences for haemophilia A treatments: A discrete choice experimentJun Su, Nanxin Li, Namita Joshi, et al.
Pageof 4

Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
Journal of Comparative Effectiveness Research|June 30, 2023
Clinical and economic outcomes associated with use of anti-arrhythmic drugs versus ablation in atrial fibrillationJennifer Ken-Opurum, Sesha Ss Srinivas, Seojin Park, et al.
BMC Family Practice|November 8, 2008
Improved persistence and adherence to diuretic fixed-dose combination therapy compared to diuretic monotherapyBimal V Patel, Rosemay A Remigio-Baker, Patrick Thiebaud, et al.
Journal of Health Economics and Outcomes Research|May 1, 2025
Healthcare Resource Utilization and Costs Related to Falls and Fractures Among People With Type 2 Diabetes Receiving Basal Insulin: The FRAGILE StudyGuillermo E Umpierrez, Elizabeth K Pogge, Xuan Li, et al.
Journal of Medical Economics|November 2, 2023
The economic value of insulin glargine 300 U/mL (Gla-300) in people ≥18 years of age with type 2 diabetes mellitus: a value-based economic model from a U.S. payer perspectiveEkaterina Ponomareva, Luke Schmerold, Srinivas Sss, et al.
Transplantation and Cellular Therapy|May 11, 2026
Impact of Chronic GVHD on Patient and Caregiver Experiences in the United States: A Retrospective Social Media AnalysisShernan Holtan, Meredith Cowden, Claudine Derrien-Connors, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|January 24, 2026
Economic Benefits of T-cell-depleting Induction in Deceased Donor Kidney Transplant RecipientsDavid Axelrod, Krista L Lentine, Huiling Xiao, et al.
Journal of Clinical Hypertension (Greenwich, Conn.)|September 6, 2007
Effects of initial antihypertensive drug class on patient persistence and compliance in a usual-care setting in the United StatesBimal V Patel, Rosemay A Remigio-Baker, Devi Mehta, et al.
Pharmacoeconomics - Open|January 31, 2020
Burden of Cardiovascular Disease in Adult Patients with Type 1 Diabetes in the USSteve Edelman, Fang Liz Zhou, Ronald Preblick, et al.
Clinical Diabetes : a Publication of the American Diabetes Association|July 17, 2023
Real-World Persistence, Adherence, Hypoglycemia, and Health Care Resource Utilization in People With Type 2 Diabetes Who Continued With the Second-Generation Basal Insulin Analog Insulin Glargine 300 Units/mL or Switched to a First-Generation Basal Insulin (Insulin Glargine 100 Units/mL or Detemir 100)Steven Edelman, Jennifer Goldman, Daniel C Malone, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|September 16, 2020
Patient and caregiver preferences for haemophilia A treatments: A discrete choice experimentJun Su, Nanxin Li, Namita Joshi, et al.
Pageof 4